Brilinta sales leaders

Quote




Better question is which regionals are tyrants and forcing tenured reps out on PIPs because managed care coverage is so crappy? Let's face it, raising the price is not going to put Brilinta on teh map anytime too soon with a lot of managed care and the government. If you cannot win over the government with a drug, it dies.
 








Hahaha, the thread is titled "Brilinta sales leaders" all in the same sentence. Now that, my friends, is too funny. Those words should NEVER be in the same sentence together. This might be better titled, "Brilinta and lack of sales leadership" or "Brilinta: no sales leadership" or Brilinta the epic failure and how management has shifted the blame to their salesforce." I think you get the point.
 




Only point is that you (last poster) can't get it done and blame everyone you can think of, and take zero responsibility on yourself. Waaaahhhh, why me ? Mommy, you told me I was special !
 




There are literally thousands of people who can be responding, but as a pure victim, must assume it is the person you want it to be. Do you realize how foolish you sound always assuming it's one specific person, as opposed to many different people trying to reply? I could really care less aout your constant need to blame someone, but a lot of folks delight in sparring with you on here.
 




Anonymous said:
There are literally thousands of people who can be responding, but as a pure victim, must assume it is the person you want it to be. Do you realize how foolish you sound always assuming it's one specific person, as opposed to many different people trying to reply? I could really care less aout your constant need to blame someone, but a lot of folks delight in sparring with you on here.
Click to expand...



Do YOU realize how foolish you LOOK? Go look in the mirror skippy, then you can laugh the rest of the night. If your face doesn't make you sick looking at it. It does make us sick. just reading your writting make us want to puke!
 




















Anonymous said:
There sure has been a LOT of post removed from this thread.

Nice job HR.
Click to expand...

I noticed that as well. Upper management can't make up their mind on Brilinta.... Could some explain how the quotas are set ?


Every sales reports states that AZ can't really say how much volume is of the OAP market is ACS but they are assigning quotas ? They are firing people for not meeting quota but no one will say how the quota is set ?

Every part of the country is so different, in some parts the Clinical cards do treat ACS and some parts they don't.

More over giving the same quota to territories that have half the volume of others ?


The mixed messages from management are ridiculous... be ethical with the customers but we won't treat you in an ethical manner ?
 








Anonymous said:
What district is leading the nation in Brilinta sales and who is the DSM?
Click to expand...

Brillinta Sales Leadrs. Isn't that an oxymoron? Brillinta and sales should not be used in the same sentence. Unless you are referring to a lack of sales. Being a Brillinta sales leader is like winning the award for being the tallest midget.
 




With Plavix gone generic, payers aim to cut Effient, Brilinta
May 29, 2012 | By Tracy Staton

Look out, Brilinta and Effient. Payers are targeting your patients. Now that rival bloodthinner Plavix is off patent, health plans will be fielding new programs to encourage switching to the cheaper generic. Worries about the one-third of patients known to respond poorly to Plavix nothwithstanding.

As The Wall Street Journal reports, Eli Lilly's ($LLY) Effient and AstraZeneca's ($AZN) Brilinta boast much smaller shares of the bloodthinner market than Plavix does. The companies have marketed these drugs as alternatives to Plavix, particularly for patients who have the genetic variation thought to dampen Plavix response.

Neither Effient nor Brilinta appear to be affected by the genetic quirk. But they are far more expensive now that Plavix copies are on the market. Generic versions are expected to cost about $1 a day at first, compared with $7.68 per day for Brilinta and $6.38 for Effient. Brand-name Plavix runs $6.44 per day, the WSJ says.

"We have switching programs to help get patients to the lowest cost agent," Express Scripts CMO Steve Miller told the WSJ. And some new research suggests that moving patients to Plavix from Effient may not make a difference in outcomes. In one study, screening patients for the genetic variant, then switching the patients at risk for poor Plavix response to Effient, didn't affect the number of heart attacks. (The patients studied were stable, however, so the results may not apply to higher-risk patients.)

Others say caution is still in order. Doctors at Brigham and Women's Hospital in Boston are making Brilinta their preferred drug, WSJ says. A Long Island cardiologist uses Effient for most patients to avoid the Plavix-response risk, turning to Brilinta for higher-risk patients. Now that Plavix has gone generic, he's using a daignostic test that measures Plavix response, expecting payers to demand backup for his prescribing the more expensive drugs.
 




So 2Q results out soon - how are the brilinta sales going guys? Tell me it's picking up, tell me it's not a busted flush, tell me it's a slow burner that is showing signs of life. please
 




















Top Bottom
Back
Quote